This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Clinical TrialsClinical TrialsLORVIQUA® Clinical TrialsPhase I/II StudyCROWN StudySafetySafetyLORVIQUA® Safety ProfileDosingDosingLORVIQUA® DosingResourcesResourcesLORVIQUA® ResourcesCase StudiesVideosMaterials

The content of this webpage has been produced in line with the LORVIQUA®▼ (lorlatinib) Summary of Product Characteristics for Great Britain.
If you are an HCP in Northern Ireland click here.
LORVIQUA®▼ (lorlatinib) Prescribing Information for Great Britain and Northern Ireland click here. XALKORI® (crizotinib) Prescribing Information for Great Britain and Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

LORVIQUA® - Great Britain
Meet ALK+ advanced NSCLC Head On with  LORVIQUA®1,2 Clinical Trials

Clinical trial information, including study design and efficacy results

 See ResultsLoadingSafety

Important safety information and safety outcomes from clinical trials

Learn MoreLoadingDosing

Dosing and monitoring requirements for LORVIQUA®

More InformationLoading

LORVIQUA® as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor or whose disease has progressed after prior treatment with an ALK inhibitor.1

A third-generation ALK TKI, LORVIQUA® is designed to address the unmet medical needs of CNS progression and ALK resistance mutations in patients with ALK+ advanced NSCLC and has demonstrated efficacy in both treatment-naïve patients and those whose disease had progressed on a previous ALK TKI.2-6

As a 2nd line therapy LORVIQUA® has a generally manageable safety profile, with a low permanent discontinuation rate (3.4%) due to treatment-related AEs* and a once-daily dosing schedule, taken with or without food.1,7

AE: Adverse Event, ALK: Anaplastic Lymphoma Kinase, CNS: Central Nervous System,  mNSCLC: metastatic Non-Small Cell Lung Cancer,  NSCLC: Non-Small Cell Lung Cancer, TKI: Tyrosine Kinase Inhibitor

Footnotes
*In the phase II portion of the Phase I/II registrational study (n=295), 3.4% of patients discontinued treatment due to a treatment-related adverse event.1,7ReferencesLORVIQUA® Summary of Product Characteristics for Great Britain click here. Solomon BJ, et al. Lancet Oncol. 2018;19(12):1654-1667.Gainor JF, et al. Cancer Discov. 2016;6:1118–33.Johnson TW, et al. J Med Chem. 2014;57:4720−44.Shaw AT, et al. N Engl J Med. 2020;383:2018–29.Lovly CM, et al. Sci Transl Med. 2012;4:120ps2.Felip E, et al. Annals of Oncology. 2021;32(5):620-630.LORVIQUA®▼ (lorlatinib) Prescribing Information for Great Britain and Northern Ireland click here.
XALKORI® (crizotinib) Prescribing Information for Great Britain and Northern Ireland click here.
PP-LOR-GBR-0448. November 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​